Latest news with #PRV
Time of India
7 days ago
- Time of India
11 cops suspended for assaulting livestock trader, extorting Rs 10k
Kanpur: Eleven police personnel were suspended for attacking a livestock trader from Aligarh and extorting Rs 10,000 from him in Kanpur on Saturday. Following a formal complaint, the additional deputy commissioner of police, south, initiated an investigation which revealed that the personnel left their assigned spot of duty to extort money from the trader. According to police, livestock trader Mohammad Uzair and driver Laxman were transporting animals from Sarsaul in Kanpur to Aligarh when they were attacked and robbed of Rs 10,000 by PRV personnel in Chakeri area. Deputy commissioner of police (DCP), south, Deependra Nath Chaudhary ordered an investigation and after preliminary investigation, suspended 11 personnel. The complainant alleged that while he was passing through Barra, personnel from a police response vehicle (PRV 7058) in Chakeri stopped him and demanded payment for transportation of animals. "Subsequently, PRV units (6504 & 7055) from Hanumant Vihar police station also reached the spot and insisted on a payment of Rs 500 per policeman for passage," he claimed. He said that when he refused to pay, the personnel forcibly removed them from their vehicle, assaulted them, and left the spot after threatening them. The investigation established that PRV 7058 from Chakeri police station, operated by constable Atul Sachan, intercepted the animal trader's vehicle. The unit had head constable Rishirajan, and constables Hariom Singh and Rinki Rani. PRV 7055 from Hanumant Vihar included head constables Ajay Kumar Yadav and Anand Kumar, and constable Umashankar Dixit. Additionally, PRV 6504 from the same station was driven by head constable Pradeep Kumar, accompanied by Amir Hasan, constable Sonu Yadav, and Aradhana.
New Indian Express
7 days ago
- New Indian Express
11 cops suspended for extortion, assault of livestock trader in Kanpur
LUCKNOW: In a case of blatant corruption, 11 Police Response Vehicle (PRV) personnel, accused of attacking livestock trader Mohammad Uzair and extorting Rs 10,000 from him, were suspended in Kanpur. Those cops left their assigned spot to extort money from the trader and assaulted him. The incident took place on July 12. Following a formal complaint, authorities initiated an investigation and found the cops involved in the case. This led them to order the suspension of 11 personnel on Monday for allegedly assaulting and extorting money from the trader from Aligarh. The preliminary enquiry was conducted by the Additional Deputy Commissioner of Police (ADCP) South and the probe established the culpability of the cops. The suspension was implemented based on the initial findings and now a comprehensive investigation is underway by the Assistant Commissioner of Police. As per the sources, on July 12, livestock trader Mohammad Uzair and driver Laxman were transporting animals from Sarsaul to Aligarh when they were reportedly attacked and robbed of Rs 10,000 by PRV personnel in the Chakeri area under Barra police station jurisdiction.
Yahoo
14-07-2025
- Business
- Yahoo
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives for OS Animal Health, close out OST-504 (previously ADXS-504) prostate cancer study and initiate AI-driven next-gen tADC product candidate modeling New York, New York--(Newsfile Corp. - July 14, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has closed its previously announced warrant exercise inducement and exchange offer. The Company raised a total of $4.2 million in gross proceeds from the offering. The Company intends to use the net proceeds primarily to support U.S. and international regulatory and pre-commercial efforts aimed at securing accelerated marketing authorizations for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. Additionally, to develop further, advance strategic alternatives for its OS Animal Health subsidiary, close out and report on its OST-504 (previously ADXS-504) prostate cancer study, initiate artificial intelligence (AI)-driven next-gen tADC product candidate modeling and for general corporate purposes. The terms of the warrant exercise inducement and exchange offer are described in greater detail in the Company's Current Report on Form 8-K filed with the SEC on July 14, 2025. "The success of this warrant exercise inducement and exchange offer provides us with capital runway through 2026," said Paul Romness, Chairman and CEO of OS Therapies. "In the next 18 months, we intend to pursue a Biologics Licensing Authorization under the Accelerated Approval Program for OST-HER2 in human osteosarcoma that we anticipate yielding a highly valuable and saleable Priority Review Voucher ("PRV"). We plan to complete evaluation of strategic alternatives for our OST-HER2 canine osteosarcoma program under our wholly owned OS Animal Health subsidiary, and report a final data readout for our OST-504 prostate cancer program. We also intend to initiate an AI-driven product candidate modeling exercise for our tunable ADC program to create new classes of next generation therapeutic candidates that address multiple complementary mechanisms across solid tumors leveraging our unique SiLinkers™ platform." Mr. Romness continued, "We remain focused on our regulatory plan: End of Phase 2 Meeting with the FDA in the United States and our Scientific Advice Meetings in the United Kingdom and Europe. This delivers on our core mission of improving the treatment landscape for metastatic osteosarcoma patients. We are cognizant that we have significant value in our pipeline programs that we can now begin to evaluate more thoroughly while minimizing cash spend. With the breadth of the technologies we have assembled, we are poised to begin improving the cancer therapeutic landscape in the years ahead." This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. This information concerns product candidates that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). These product candidates are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the FDA and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. OS Therapies Contact Information: Investor RelationsHarrison Seidner, PhDWaterSeid PartnersOSTX@ Public RelationsStephanie ChenElev8 New Mediastephanie@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
18-06-2025
- Business
- Yahoo
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by chikungunya virus in people 12 years of age and older. Pursuant to a license agreement assumed upon acquisition of the chikungunya vaccine in 2023, National Institutes of Health (NIH) will receive 20% of the gross proceeds from the sale of the PRV. The proceeds will be recognized as other operating income and thus will not impact the guided revenue expectations for 2025. However, EBITDA will be positively impacted and any impact on the guided EBITDA margin of 26-30% for 2025 will be updated upon closing of the transaction. The transaction remains subject to customary closing conditions, including anti-trust review, which is expected to occur in the third quarter of 2025. Jefferies LLC acted as exclusive financial advisor to Bavarian Nordic on this transaction. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@ Tel: +45 61 77 47 43US: Graham Morrell, Gilmartin Group, graham@ Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@ Tel: +45 53 88 06 03 Company Announcement no. 18 / 2025 Attachment 2025-18-enError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
09-06-2025
- Business
- Mint
Five shipbuilding stocks to watch as India strengthens ties with Japan
India is moving at a rapid pace on its journey to become a global hub for shipbuilding. The government has finalised a fresh round of international partnerships, including a major push with Japan, to strengthen the country's maritime capabilities. In a recent bilateral meeting in Oslo, Indian shipping minister Sarbananda Sonowal and Japan's vice minister Terada Yoshimichi discussed a broad range of areas—from shipbuilding and maritime training to green ports and smart island development in Andaman & Nicobar and Lakshadweep. A key focus was encouraging Japanese investment in Indian shipyards, opening doors for technology transfer and capital support from some of Japan'sleading maritime companies. Here are a fewshipbuilding stocks that could benefit from this growing India-Japan collaboration. #1 Garden Reach Shipbuilders Garden Reach Shipbuilders is already seeing direct benefits from these international maritime collaborations. The company caters to the shipbuilding requirements of the Indian Navy and the Indian Coast Guard. It builds vessels, i.e. frigates, missile corvettes, anti-submarine warfare corvettes, survey vessels, offshore patrol vessels, etc. Over the years, GRSE has also supplied various boats, pontoons, and barges. It owns three separate shipbuilding facilities close to each other in Kolkata. The ships are built at the Main Works Unit and the Rajabagan Dockyard. As part of India's recent global outreach in maritime partnerships, GRSE signed a significant Memorandum of Understanding (MoU) with Norwegian firm Kongsberg during the Nor-Shipping 2025 event in Oslo. The MoU sets the stage for India's first-ever Polar Research Vessel (PRV). This highlights India's commitment to advancing oceanic and polar research capabilities while strengthening its indigenous shipbuilding industry under the 'Make in India' initiative. The PRV will be developed with design expertise from Kongsberg and constructed by GRSE in Kolkata. It will cater to the requirements of the National Centre for Polar and Ocean Research (NCPOR), enabling scientific exploration in the polar and Southern Ocean regions. GRSE is focusing on developing cutting-edge technology for the next generation of warships, like unmanned surface vessels (USVs), leveraging artificial intelligence (AI) and machine learning (ML). #2 L&T Larsen & Toubro (L&T) is one of the major players in the shipbuilding industry, offering a wide range of services from designing and building new vessels to repairing and refitting existing ones. It operates shipyards in Kattupalli, near Chennai, and Hazira, according to L&T India. L&T's shipbuilding arm specialises in both defence and commercial vessels, including warships, submarines, auxiliary vessels, and specialised commercial ships. It entered into a major MoU with Norway's DNV, aimed at collaboration in several sectors. This partnership covers shipbuilding, offshore and maritime and expanding port Infrastructure, energy systems, industrial solutions and smart Infrastructure, sustainability, ESG and risk services, software, cyber security, platforms and digital solutions. Going forward, the company plans to expand its defence business, leveraging its Kattupalli shipyard. Also Read: Realty firms are on a high after last year's spending spree to buy land #3 Cochin Shipyard Cochin Shipyard Limited (CSL) stands out as one of India's most modern and advanced shipyards. Incorporated in 1972, CSL is a leading player in the construction, repairs, and refits of all kinds of vessels,including periodic upgradation and life extension of ships. CSL has built and repaired some of the largest ships in India and has recently delivered the prestigious Indigenous Aircraft Carrier to the Indian Navy, the largest warship ever built in India. It has developed its expertise from building bulk carriers to smaller ships and ships which are more advanced in terms of technology such as Platform Supply vessels, and Anchor Handling Tug Supply Vessels. It has a significant focus on building warships for the Indian Navy. Given this expertise in building advanced vessels, Cochin Shipyard is well-equipped to benefit from the recent India-Japan maritime collaboration. Looking ahead, the company is investing ₹2,800 crore in infrastructure expansion, including a new dry dock and ship repair yard in Kochi, to enhance capacity for building and maintaining large warships. #4 Swan Defence & Heavy Industries Swan Defence & Heavy Industries, formerly Reliance Naval and Engineering Ltd, isan Indian shipbuilding and heavy industry company. The company operates India's largest shipyard, located near Pipavav, Gujarat. It is a prominent player in both commercial and defence shipbuilding, offering a range of services including shipbuilding, ship repair/retrofit, and heavy fabrication. It offers facilities for new builds and repairs of commercial and defence vessels, repairs for Jack-Up Rigs, offshore vessels and heavy fabrication for offshore projects in oil & gas, yellow goods and offshore wind farms. With its expansive shipyard and wide-ranging expertise, Swan Defence is well-placed to become an ideal partner for joint ventures, tech collaborations, or subcontracting deals that could emerge from the growing India-Japan maritime alliance. Going forward, the company plans to become a major player in naval defence and oil and gas vessels. #5 Marine Electricals Marine Electricals is an integrated electrical and automation solutions provider for the marine and industry/commercial sectors. Marine Electricals specializes in delivering innovative system solutions and reliable maintenance services for various ships, including naval, coast guard, container, and passenger vessels, as well as offshore and research crafts. Since its establishment in 1978, Marine Electricals has emerged as a pioneering force in the global maritime industry, offering comprehensive electrical and electronic solutions. The company's services encompass ship-wide cable laying solutions, equipment installation, and package solutions for shipyards. With decades of expertise in electrical automation, smart systems, and integrated ship solutions, the company is well-aligned to contribute meaningfully to these emerging priorities. Being part of the Indian delegation to Norway, not only highlights Marine Electricals' growing relevance in the sector but also places it in a strong position to explore international partnerships. Going forward, the company plans to expand its reach. Conclusion India is swiftly reshaping its maritime sector with bold initiatives like Maritime India Vision 2030 and Maritime Amrit Kaal Vision 2047. Thanks to the strong partnership with Japan, India is set to draw investments worth 5 trillion yen (around ₹3.2 trillion) by 2027, creating exciting opportunities for sustainable growth and innovation in shipbuilding, port modernisation, and smart island development. These are set to benefit the stocks in the shipbuilding space. However, it's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from
